ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Wakamoto Pharmaceutical Co., Ltd. ?
1
Poor Management Efficiency with a low ROE of 0.95%
- The company has been able to generate a Return on Equity (avg) of 0.95% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of 0.41% over the last 5 years
3
Flat results in Mar 26
- PRE-TAX PROFIT(Q) At JPY 33.81 MM has Fallen at -62.45%
- NET PROFIT(Q) At JPY 12.17 MM has Fallen at -83.69%
- DEBT-EQUITY RATIO (HY) Highest at -13.38 %
4
With ROE of 2.47%, it has a expensive valuation with a 1.02 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -13.40%, its profits have risen by 0.7% ; the PEG ratio of the company is 41.2
- At the current price, the company has a high dividend yield of 0
5
Below par performance in long term as well as near term
- Along with generating -13.40% returns in the last 1 year, the stock has also underperformed Japan Nikkei 225 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Wakamoto Pharmaceutical Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Wakamoto Pharmaceutical Co., Ltd. for you?
Low Risk, Low Return
Absolute
Risk Adjusted
Volatility
Wakamoto Pharmaceutical Co., Ltd.
-13.4%
0.13
33.68%
Japan Nikkei 225
85.83%
3.09
27.80%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
0.41%
EBIT Growth (5y)
15.97%
EBIT to Interest (avg)
-256.03
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.25
Sales to Capital Employed (avg)
0.68
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
161.58%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.35%
ROE (avg)
0.95%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
41
Industry P/E
Price to Book Value
1.02
EV to EBIT
149.83
EV to EBITDA
20.88
EV to Capital Employed
1.02
EV to Sales
1.15
PEG Ratio
41.18
Dividend Yield
NA
ROCE (Latest)
0.68%
ROE (Latest)
2.47%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend20What is working for the Company
NET PROFIT(HY)
Higher at JPY 361.23 MM
ROCE(HY)
Highest at 1.92%
DIVIDEND PAYOUT RATIO(Y)
Highest at 998%
RAW MATERIAL COST(Y)
Fallen by -1.01% (YoY
DIVIDEND PER SHARE(HY)
Highest at JPY 3.22
NET SALES(Q)
At JPY 2,596.39 MM has Grown at 11.76%
-22What is not working for the Company
PRE-TAX PROFIT(Q)
At JPY 33.81 MM has Fallen at -62.45%
NET PROFIT(Q)
At JPY 12.17 MM has Fallen at -83.69%
DEBT-EQUITY RATIO
(HY)
Highest at -13.38 %
INVENTORY TURNOVER RATIO(HY)
Lowest at 1.49 times
CASH AND EQV(HY)
Lowest at JPY 3,676.96 MM
INTEREST(Q)
Highest at JPY 1.15 MM
Here's what is working for Wakamoto Pharmaceutical Co., Ltd.
Net Sales
At JPY 2,596.39 MM has Grown at 11.76%
over average net sales of the previous four periods of JPY 2,323.26 MMMOJO Watch
Near term sales trend is positive
Net Sales (JPY MM)
Dividend per share
Highest at JPY 3.22
in the last five yearsMOJO Watch
Company is distributing higher dividend from profits generated
DPS (JPY)
Dividend Payout Ratio
Highest at 998%
in the last five yearsMOJO Watch
Company is distributing higher proportion of profits generated as dividend
DPR (%)
Raw Material Cost
Fallen by -1.01% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at JPY 114.27 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (JPY MM)
Here's what is not working for Wakamoto Pharmaceutical Co., Ltd.
Pre-Tax Profit
At JPY 33.81 MM has Fallen at -62.45%
over average net sales of the previous four periods of JPY 90.03 MMMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (JPY MM)
Net Profit
At JPY 12.17 MM has Fallen at -83.69%
over average net sales of the previous four periods of JPY 74.65 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (JPY MM)
Interest
At JPY 1.15 MM has Grown at 511.7%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
Debt-Equity Ratio
Highest at -13.38 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Inventory Turnover Ratio
Lowest at 1.49 times and Fallen
In each half year in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Interest
Highest at JPY 1.15 MM
in the last five periods and Increased by 511.7% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
Cash and Eqv
Lowest at JPY 3,676.96 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
